{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "10097744",
  "DateCompleted": {
    "Year": "1999",
    "Month": "04",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2013",
    "Month": "11",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "jpn"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0385-0684",
      "JournalIssue": {
        "Volume": "26",
        "Issue": "4",
        "PubDate": {
          "Year": "1999",
          "Month": "Mar"
        }
      },
      "Title": "Gan to kagaku ryoho. Cancer & chemotherapy",
      "ISOAbbreviation": "Gan To Kagaku Ryoho"
    },
    "ArticleTitle": "[Clinical evaluation of S-1, a new anticancer agent, in patients with advanced gastrointestinal cancer. S-1 Cooperative Gastrointestinal Study Group].",
    "Pagination": {
      "StartPage": "476",
      "EndPage": "485",
      "MedlinePgn": "476-85"
    },
    "Abstract": {
      "AbstractText": [
        "In developing a new anticancer agent, it is most important to balance the antitumor activity and toxicity of the agent. S-1 was designed to achieve high activity and low toxicity. In it tegafur, a prodrug of 5-FU, is combined with two classes of modulators. CDHP, an inhibitor of 5-FU degradation in the liver, and Oxo, an inhibitor of 5-FU phosphoribosylation in the digestive tract. In both early and late Phase II studies, S-1 was effective against advanced or recurrent gastrointestinal cancer. Toxicities were generally mild, and there were no toxic deaths."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Surgery II, Kyushu University School of Medicine, Fukuoka, Japan."
          }
        ],
        "LastName": "Maehara",
        "ForeName": "Y",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Sugimachi",
        "ForeName": "K",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kurihara",
        "ForeName": "M",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Taguchi",
        "ForeName": "T",
        "Initials": "T"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Clinical Trial, Phase II",
      "English Abstract",
      "Journal Article",
      "Multicenter Study"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Japan",
    "MedlineTA": "Gan To Kagaku Ryoho",
    "NlmUniqueID": "7810034",
    "ISSNLinking": "0385-0684"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antimetabolites, Antineoplastic"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Drug Combinations"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pyridines"
    },
    {
      "RegistryNumber": "150863-82-4",
      "NameOfSubstance": "S 1 (combination)"
    },
    {
      "RegistryNumber": "1548R74NSZ",
      "NameOfSubstance": "Tegafur"
    },
    {
      "RegistryNumber": "5VT6420TIG",
      "NameOfSubstance": "Oxonic Acid"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Oral"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antimetabolites, Antineoplastic"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Colonic Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Administration Schedule"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Combinations"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Oxonic Acid"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Pyridines"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Rectal Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Remission Induction"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Stomach Neoplasms"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Tegafur"
    }
  ]
}